Background-Identifying reversible renal dysfunction (RD) in the setting of heart failure is challenging. The goal of this study was to evaluate whether elevated admission blood urea nitrogen/creatinine ratio (BUN/Cr) could identify decompensated heart failure patients likely to experience improvement in renal function (IRF) with treatment. Methods and Results-Consecutive hospitalizations with a discharge diagnosis of heart failure were reviewed. IRF was defined as ≥20% increase and worsening renal function as ≥20% decrease in estimated glomerular filtration rate. IRF occurred in 31% of the 896 patients meeting eligibility criteria. Higher admission BUN/Cr was associated with inhospital IRF (odds ratio, 1.5 per 10 increase; 95% confidence interval [CI], 1.3-1.8; P<0.001), an association persisting after adjustment for baseline characteristics (odds ratio, 1.4; 95% CI, 1.1-1.8; P=0.004). However, higher admission BUN/Cr was also associated with post-discharge worsening renal function (odds ratio, 1.4; 95% CI, 1.1-1.8; P=0.011). Notably, in patients with an elevated admission BUN/Cr, the risk of death associated with RD (estimated glomerular filtration rate <45) was substantial (hazard ratio, 2.2; 95% CI, 1.6-3.1; P<0.001). However, in patients with a normal admission BUN/Cr, RD was not associated with increased mortality (hazard ratio, 1.2; 95% CI, 0.67-2.0; P=0.59; p interaction=0.03). Conclusions-An elevated admission BUN/Cr identifies decompensated patients with heart failure likely to experience IRF with treatment, providing proof of concept that reversible RD may be a discernible entity. However, this improvement seems to be largely transient, and RD, in the setting of an elevated BUN/Cr, remains strongly associated with death. Further research is warranted to develop strategies for the optimal detection and treatment of these high-risk patients. (Circ Heart Fail. 2013;6:233-239.)
R enal dysfunction (RD) is a common finding in heart failure (HF) and has emerged as one of the most potent prognostic indicators in these patients. 1, 2 However, multiple different mechanisms capable of initiating a reduction in glomerular filtration rate (GFR) exist in HF, and the mechanism underlying the reduction in GFR likely has important prognostic and therapeutic implications. [3] [4] [5] [6] Unfortunately, limited progress has been made with respect to differentiation of these potential mechanistic subtypes of RD.
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The blood urea nitrogen/creatinine ratio (BUN/Cr) has been extensively used in clinical medicine for the differentiation of prerenal RD from intrinsic renal parenchymal disease. 7 The discriminative ability of BUN/Cr is based on the intrarenal mechanisms governing tubular urea handling. In the setting of a prerenal stressor, such as dehydration, significant renal neurohormonal activation (ie, increases in vasopressin, renal sympathetic nerve activity, and the renin-angiotensin-aldosterone axis) causes a disproportionate reabsorption of urea compared with that of creatinine. [8] [9] [10] [11] Similarly, HF-induced RD has also traditionally been classified as a prerenal form of RD, and renal neurohormonal activation is hypothesized to represent a prominent mechanistic contributor to the genesis of this form of RD. 12 As such, the same physiology that allows BUN/Cr to differentiate chronic intrinsic kidney disease from dehydration should also apply to differentiation of HF-induced RD. Notably, we have recently reported that BUN/Cr can differentiate clinically important subgroups of RD as evidenced by the finding that essentially all of the mortality risk attributable to RD is confined to patients with an elevated BUN/Cr. improvement in renal function (IRF) seems to occur in up to 30% of acutely decompensated HF patients with their return to compensation supports this possibility. 13, 14 Given that an elevated BUN/Cr is often associated with reversible prerenal physiology, we hypothesized that an elevated admission BUN/ Cr would identify patients with reversible HF-induced RD that would improve with treatment of their decompensated HF. However, given that IRF is transient in the majority of patients, we also hypothesized that, despite this potential reversibility, RD, in the setting of an elevated BUN/Cr, would still be associated with worsened survival. 13, 14 The primary aim of this study was to determine whether baseline BUN/Cr could identify patients with reversible RD and to validate, in the same population, our previous observations that RD in the setting of an elevated BUN/Cr is associated with substantially worsened survival.
Methods
Consecutive admissions from 2004 to 2009 to the cardiology and internal medicine services at the Hospital of the University of Pennsylvania with a primary discharge diagnosis of congestive HF were reviewed. Inclusion required an admission B-type natriuretic peptide level of >100 pg/mL within 24 hours of admission, a length of stay of 3 to 14 days, and availability of serum creatinine and BUN levels. There were 7 patients without admission serum BUN levels available who met all other inclusion criteria, accounting for the slightly lower number of patients in this cohort than the parent cohort from which it was derived. 13 Patients on renal replacement therapy or those admitted to interventional cardiology services (to avoid confounding from contrast nephropathy) were excluded. In the event of multiple hospitalizations for a single patient, the first admission was retained. Post-discharge renal function was ascertained in the subset of patients with data available as previously described. 13 Estimated GFR (eGFR) was calculated using the 4-variable modified diet and renal disease equation. 15 Unless otherwise noted, IRF was defined as a ≥20% increase at any time during the hospitalization and post-discharge worsening renal function (WRF) as a ≥20% decrease in eGFR from the discharge to the outpatient value, consistent with previously published studies of IRF and WRF. 3, 5, 6, 13, 14, 16, 17 All-cause mortality was determined via the Social Security death index. 18 Loop diuretic doses were converted to furosemide equivalents with 1 mg bumetanide =20 mg torsemide =80 mg furosemide for oral diuretics, and 1 mg bumetanide =20 mg torsemide =40 mg furosemide for intravenous diuretics. The study was approved by the institutional review board of the Hospital of the University of Pennsylvania.
Statistical Analysis
The primary goal of this analysis was to evaluate the association between admission BUN/Cr and IRF during treatment of acute decompensated HF. For the purposes of the primary analysis and unless otherwise specified, BUN/Cr was treated as a continuous covariate. ). 4 Statistical significance was determined with the log-rank test. Stratum-specific HRs and 95% confidence intervals (CIs) were derived from proportional hazards modeling of the individual strata, and the significance of the interactions was formally assessed in models incorporating terms for the main effect of renal function, the main effect of BUN/Cr, and the interaction between these variables. Statistical analyses were performed using Stata 12.0 (Statacorp, College Station, TX), and statistical significance was defined as a 2-sided P value <0.05, with the exception of tests of interaction where significance was defined as a P value <0.1.
Results
Overall, 896 patients met the inclusion criteria. Thirty-one percent of the population (n=278) experienced IRF during hospitalization with a mean improvement in eGFR in these patients of 43.7±27.2%. The remainder of the cohort experienced a mean improvement in eGFR from admission to the highest eGFR during hospitalization of only 5.3±6.7%. A detailed description of baseline characteristics, influence of treatment, and prognosis associated with IRF has previously been described. 13 The mean baseline BUN/Cr in the cohort was 18.6±7.7 with a median value of 17 and an interquartile range of 13.3 to 22.2. Baseline BUN/Cr demonstrated very weak correlations with both admission serum creatinine (r=0.071; P=0.03) and eGFR (r=0.18; P<0.001). Baseline characteristics of patients with and without a BUN/Cr ≥20 are shown in Table 1 . Notably, patients with an elevated BUN/ Cr were more likely to be white, to be older, and to have an ischemic cause for their HF. Markers of venous congestion were more prevalent in patients with an elevated BUN/Cr, including an elevated jugular venous pressure and presence of peripheral edema. Additionally, the elevated BUN/Cr group had multiple baseline indices consistent with greater HF disease severity, including lower baseline eGFR, serum sodium, hemoglobin, and systolic blood pressure, and a higher B-type natriuretic peptide.
The admission BUN/Cr was significantly associated with IRF (OR, 1.5 per 10 increase in BUN/Cr; 95% CI, 1.3-1.8; P<0.001) (Figure 1) . The association between BUN/Cr and IRF was linear across values of BUN/Cr as evaluated graphically with a lowess smoother. 19 Patients with higher BUN/Cr also had a significantly greater likelihood of continuing to meet criteria for IRF at the time of discharge (OR, 1.5; 95% CI, 1.2-1.8; P<0.001). The BUN/Cr remained associated with IRF after adjustment for baseline eGFR (OR, 1.4; 95% CI, 1.2-1.7; P<0.001) and baseline factors associated with IRF (age, race, hypertension, diabetes mellitus, ischemic HF pathogenesis, jugular venous distention, ejection fraction, systolic blood pressure, loop diuretic dose, angiotensin converting enzyme or angiotensin receptor blocker use, β-blocker use, spironolactone use, thiazide use, nitrate use, B-type natriuretic peptide level, serum sodium, and serum hemoglobin) (OR, 1.4; 95% CI, 1.1-1.8; P=0.004). Results were similar when comparing BUN/ Cr ≥20 with BUN/Cr <20, the top BUN/Cr quartile versus the remainder of population, the top BUN/Cr tertile versus the remainder of population, and BUN/Cr above and below the median for both the adjusted and unadjusted analyses ( Table 2) . Admission BUN demonstrated a significant univariate association with IRF (OR, 1.02; 95% CI, 1.01-1.02; P<0.001). When both admission BUN and BUN/ Cr were examined together in a regression model adjusted for admission eGFR, only BUN/Cr retained a significant relationship with IRF (BUN/Cr OR, 1.4; 95% CI, 1.09-1.82; P=0.01; BUN OR, 1.0; 95% CI, 0.99-1.01; P=0.93).
In the overall population, BUN/Cr increased on average 16.6±40.2% from admission to discharge (P<0.001). Interestingly, there was not a significant difference in the degree of increase in BUN/Cr between patients that met 
Baseline BUN/Cr, RD, and Mortality
Forty-four percent of the population died during a median follow-up of 2.6 years. Baseline BUN/Cr was significantly associated with increased mortality in this population (HR, 1.8 per 10 increase; 95% CI, 1.6-2.0; P<0.001), an association that persisted when adjusted for baseline eGFR (Table 3) . Adjusting for baseline characteristics, chronic medical conditions, medication use, and admission laboratory data did not eliminate the independent association of increasing BUN/Cr with mortality (Table 3) . Admission eGFR was also significantly associated with mortality (HR, 1.1 per 10 mL/min per 1.73 m 2 decrease in eGFR; 95% CI, 1.1-1.2; P<0.001), an association which persisted after adjustment for baseline BUN/Cr (HR, 1.1 per 10 mL/min per 1.73 m 2 decrease in eGFR; 95% CI, 1.1-1.2; P<0.001) and baseline characteristics (HR, 1.1 per 10 mL/min per 1.73 m 2 decrease in eGFR; 95% CI, 1.0-1.1; P=0.017). Consistent with our previously published findings in other populations, there was significant effect modification by BUN/Cr on the association between eGFR and mortality (p interaction for continuous variables =0.04). 4 Notably, in patients with a BUN/Cr in the top quartile, the risk of death associated with admission eGFR remained significant (HR, 1.2 per 10 mL/min per 1.73 m 2 decrease in eGFR; 95% CI, 1.1-1.3; P<0.001). However, in patients with a BUN/Cr in the bottom quartile, eGFR was no longer associated with death (HR, 1.0 per 10 mL/min per 1.73 m 2 decrease in eGFR; 95% CI, 0.97-1.1; P=0.25; p interaction=0.029). Consistent with our previously published findings, this effect modification was strengthened by adjustment for baseline characteristics, including age, sex, race, hypertension, coronary artery disease, B-type natriuretic peptide, serum sodium, systolic blood pressure, heart rate, loop diuretic dose, and angiotensin converting enzyme inhibitor or angiotensin receptor blocker use (p interaction for continuous variables=0.016). Similar results were noted when eGFR was dichotomized to patients with or without moderateto-severe RD (eGFR ≤45 mL/min per 1.73 m 2 ), where the risk associated with RD was substantial in those with a BUN/Cr in the top quartile (HR, 2.2; 95% CI, 1.6-3.1; P<0.001) and undetectable in those with a BUN/Cr in the bottom quartile (HR, 1.2; 95% CI, 0.67-2.0; P=0.59; p interaction =0.03) (Figure 2 ). Although the risk of death associated with RD also differed between those with an admission BUN in the top versus bottom quartile (p interaction=0.08), when both the interaction between admission BUN and RD as well as the interaction between admission BUN/Cr and RD were examined in the same model, only the interaction between BUN/Cr and RD remained significantly associated with mortality (p interaction BUN/Cr×RD=0.03; p interaction BUN×RD=0.26).
Discussion
The primary finding of this study is the strong association between an elevated admission BUN/Cr and significant improvement in kidney function during the treatment of acute decompensated HF. Even after adjustment for comorbidities known to impact renal function, as well as medications that influence GFR, an elevated BUN/Cr at admission continued to be strongly associated with IRF. However, the IRF observed after standard decompensated HF treatment was frequently transient, and RD in the setting of an elevated BUN/ Cr remained strongly associated with reduced survival. These findings provide proof of concept that not only may prospective identification of potentially reversible forms of RD be possible, but also that this form of RD seems to represent, perhaps, the most prognostically important cardiorenal phenotype in HF.
Urea plays a fundamental and direct role in fluid and sodium homeostasis, processes tightly regulated by neurohormonal systems. 8, 9, 20, 21 As a result, during times of fluid and sodium avidity, such as intravascular volume depletion or HF, the rate of urea excretion is reduced out of proportion to the reduction in GFR, ultimately leading to an elevated BUN/ Cr. 10, 22 However, with intrinsic renal parenchymal disease, the primary defect leading to RD is irreversible nephron loss rather than neurohormonal activation. As a result, the rate of urea clearance is reduced in parallel to GFR, resulting in a normal BUN/Cr. This neurohormonally mediated disassociation between urea reabsorption and glomerular filtration forms the basis for the widespread clinical application of BUN/Cr for the differentiation of prerenal RD from intrinsic renal parenchymal disease. Given the key role for neurohormones in the pathogenesis of both HF and reversible prerenal forms of RD, this physiology may represent the common thread linking the finding of reversibility and the increased risk for death.
We have previously reported that the majority of patients who experience IRF during the treatment of decompensated HF actually have post-discharge recurrence of the RD. 13, 14 Similarly, in the current analysis, we found that an elevated admission BUN/Cr was also associated with an increased incidence of post-discharge WRF, independent of the discharge eGFR or changes in eGFR during hospitalization. These observations allow some speculation as to how BUN/ Cr could identify a form of RD that is potentially reversible and also associated with significantly increased mortality. Because currently available HF treatments are not capable of increasing renal function to supranormal levels, for improvement in kidney function to be possible, reversible RD must be present at baseline (with the most likely pathogenesis being RD induced by severe HF). Given that patients experiencing IRF were likely sicker at baseline and the improvement in disease severity is largely transient, it is understandable how an elevated BUN/Cr could potentially be associated with reversible RD but also worsened survival. However, we have also previously reported that in the few patients who maintain IRF long term, there may actually be improved survival associated with the IRF. 13 Although again speculative, this observation raises the possibility that strategies aimed at inducing and maintaining IRF could potentially lead to improved outcomes. Markers, such as BUN/Cr, may allow the prospective identification of patients with the potential for IRF, facilitating interventional trials that can actually prove or disprove causality for these highly complex associations. Despite the above promising proof-of-concept findings, BUN/Cr is a less than ideal measure of renal urea handling and is influenced by non-renal factors, such as diet and protein catabolism. 23 Furthermore, creatinine-based estimates of GFR also have significant limitations secondary to factors, such as the dependence of serum creatinine on muscle mass and tubular secretion. 24 Recently, several novel renal biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-β-D-glucosaminidase (NAG), and kidney injury molecule 1 (KIM-1), have demonstrated high specificity in the detection of acute kidney injury. 25 Furthermore, at present, the widely available filtration marker cystatin C offers the advantage of limited influence from lean body mass and tubular secretion. It is reasonable to hypothesize that given the strong signals demonstratable using a crude metric, such as BUN/Cr, the aforementioned renal biomarkers may provide superior discriminative ability.
Limitations
There are several limitations that must be considered when interpreting these results. First, given the retrospective study design, causality is impossible to demonstrate and residual confounding cannot be excluded. Physicians were not blinded to measures of renal function and, thus, may have altered treatment decisions in response to these data. Furthermore, given that proven methodology to detect and optimally treat reversible RD in this population was unavailable to the treating physicians, it is highly likely that some patients with reversible RD may have been refractory to the treatment they received (or possibly received treatment that led to no improvement or worsening in renal function) and, thus, did not experience IRF. This possibility may have led to a substantial underestimation of the magnitude of the association between BUN/Cr and reversible RD. Additionally, non-neurohormonal factors, such as diet and protein catabolism, that influence urea reabsorption may have introduced potential uncontrolled confounding. Given the slow equilibration time and nonrenal factors that influence serum creatinine, assessment of IRF based on creatinine-based eGFR may also have introduced bias. The analysis of post-discharge renal function has a large degree of missing data, which are likely missing not at random and, thus, may have significant bias inherent to the results. As a result of the above limitations, our findings should be considered hypothesis-generating and serve primarily to initiate further investigation.
Conclusions
In the setting of decompensated HF, an elevated BUN/Cr identifies patients likely to experience IRF, providing proof of concept that reversible RD may be a discernible entity. However, the improved kidney function observed following standard decompensated HF treatment seems to be largely transient and, perhaps as a result, RD in the setting of an elevated BUN/Cr remains strongly associated with worsened survival. Further research to develop methodology for the optimal detection and treatment of these high-risk patients is warranted with the goal of facilitating sustained improvements in renal function and potentially clinical outcomes.
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